{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"AE Severity (Mild)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"AE Severity (Moderate)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"AE Severity (Severe)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Life-threatening AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"AE Relationship to Drug (Not related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"AE Relationship to Drug (Probably not related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"AE Relationship to Drug (Possibly related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"AE Relationship to Drug (Probably related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"AE Relationship to Drug (Definitely related)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Participant counts of summarized adverse events (AEs) which occurred from the first dose of plerixafor up to the day prior to chemotherapy/ablative treatment. Events were graded according to World Health Organization criteria: Mild (awareness of sign or symptom, but easily tolerated), Moderate (discomfort enough to cause interference with usual activity), Severe (incapacitating with inability to work or do usual activity).","groups":[{"description":"Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.","id":"OG000","title":"Participants With Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"All participants who received plerixafor","reportingStatus":"POSTED","timeFrame":"1 month","title":"Participant Counts of Summarized Adverse Events (AE) During Treatment","type":"PRIMARY","unitOfMeasure":"participants"}